No Data
Joincare Pharmaceutical Group Industry (600380.SH): has repurchased a total of 2.34% of shares.
On March 3, Glonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) announced that by February 2025, the company had repurchased a total of 992,800 shares through centralized bidding, accounting for 0.05% of the total share capital (1,874,200,420 shares), with the highest purchase price at 11.05 yuan/share, the lowest at 10.81 yuan/share, and a total amount paid of 10.8583 million yuan (including fees). As of the end of February 2025, the company had cumulatively repurchased 43,843,462 shares, accounting for the total share capital (1,874,200,420 shares).
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Livzon Gets Nod to Trial Reflux Esophagitis Drug
Joincare Pharmaceutical Group Industry (600380.SH): Received the drug clinical trial approval notice.
On February 12, Gelonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) announced that its holding subsidiary Livzon Pharmaceutical Group Inc. (hereinafter referred to as Livzon) received the "Drug Clinical Trial Approval Notice" (Notice No. 2025LP00349) approved and issued by the National Medical Products Administration, permitting the clinical trial of injectable JP-1366. JP-1366 is a novel potassium ion competitive acid blocker (P-CAB), which works by competitively binding to the potassium ion binding site of the H+/K+-ATPase in gastric parietal cells to inhibit gastric acid secretion. P-
Joincare Pharmaceutical Group Industry (600380.SH) subsidiary JP-1366 injection has been approved to start clinical trials.
Joincare Pharmaceutical Group Industry (600380.SH) announced that recently, the company's holding subsidiary LIVZON PHARMA...
Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Are Strong Financial Prospects The Force That Is Driving The Momentum In Joincare Pharmaceutical Group Industry Co.,Ltd.'s SHSE:600380) Stock?
